Prognostic factors in resectable gastric cancer: Results of EORTC study no. 40813 on FAM adjuvant chemotherapy

1995 ◽  
Vol 2 (6) ◽  
pp. 495-501 ◽  
Author(s):  
Mario Lise ◽  
Donato Nitti ◽  
Alberto Marchet ◽  
Tarek Sahmoud ◽  
Nicole Duez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Resectable Gastric Cancer

EFFICIENCY OF ADJUVANT XELOX CHEMOTHERAPY FOR PATIENTS WITH RESECTABLE GASTRIC IN RUSSIA (SINGLE INSTITUTION RETROSPECTIVE STUDY)

2019 ◽  
Vol 65 (2) ◽  
pp. 256-262
Author(s):  
Ivan Stilidi ◽  
Sergey Nered ◽  
Aleksey Kalinin ◽  
Olesya Rossomakhina ◽  
Anton Barchuk
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Radical Surgery ◽  
Univariate Analysis ◽  
European Population ◽  
Single Institution ◽  
Regional Lymph Nodes ◽  
Lymph Nodes Metastasis ◽  
Retrospective Assessment ◽  
Resectable Gastric Cancer

Introduction. The effectiveness of the Asian regimen of adjuvant chemotherapy in patients with gastric cancer in the European population remains unclear. The aim of our study was a retrospective assessment of adjuvant chemotherapy (XELOX regimen) after radical surgery (R0) on overall survival. Methods. Database of pts with resectable gastric cancer with stage >pT3 and/or pN+ and M0, who were operated (R0) at single oncological institution during 2007-2017 was reviewed. In univariate and multivariate analyzes were included demographic characteristics, type of tumor according to Lauren, stage, type of treatment and others. Results. 396 pts were identified and 286 were available for analysis.106 (37%) pts received at least one cycle of adjuvant chemotherapy. In univariate analysis, 5OS rate was 64% [95% Cl, 52-80] и 56% [95% Cl, 48-64; p=0,21] in patients received adjuvant chemotherapy and only surgical treatment. After stratifying patients depending on the regional lymph nodes metastasis, 5OS rate in pts with pN1-3 was 69% [95% CI, 57-85] vs 47% [95% CI, 39-58; p = 0,01], respectively...

Is There a Benefit for Added Radiation to Adjuvant Chemotherapy after D2 Gastrectomy for Resectable Gastric Cancer?

2019 ◽  
Vol 229 (4) ◽  
pp. S268
Author(s):  
Michael J. Jalfon ◽  
Miriam Tsao ◽  
Benjamin W. Deschner ◽  
Paxton V. Dickson ◽  
Jeremiah L. Deneve ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
D2 Gastrectomy ◽  
Resectable Gastric Cancer

scholarly journals Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer

PLoS ONE ◽  
2013 ◽  
Vol 8 (12) ◽  
pp. e83196 ◽  
Author(s):  
Jing-lei Qu ◽  
Xin Li ◽  
Xiu-juan Qu ◽  
Zhi-tu Zhu ◽  
Li-zhong Zhou ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Adjuvant Chemotherapy ◽  
Optimal Duration ◽  
Resectable Gastric Cancer

scholarly journals Clinical significance of peripheral blood-derived inflammation markers in advanced gastric cancer after radical resection

2020 ◽  
Author(s):  
Lihu Gu ◽  
Bangsheng Chen ◽  
Dingcheng Zheng ◽  
Jiahang Mo ◽  
Lingling Yuan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Peripheral Blood ◽  
Inflammatory Markers ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Inflammation Markers ◽  
Optimal Cutoff

Abstract Background and objective: The prognostic significance of peripheral blood-derived inflammation markers in patients with gastric cancer (GC) has not been elucidated. This study aimed to investigate the relationship between systemic inflammatory markers and GC prognosis.Methods: A prospective observational cohort study involving 598 patients was conducted to analyze the prognosis of GC based on systemic inflammatory markers. The following peripheral blood-derived inflammation markers were evaluated: the neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), systemic immune-inflammation index (SII), C-reactive protein/albumin (CRP/Alb) ratio, Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), prognostic nutrition index (PNI), and prognostic index (PI). The receiver operating characteristics (ROC) curve and the Youden index were used to determine the optimal cutoff values. Univariate and multivariate analysis of prognostic factors was conducted accordingly.Results: The optimal cutoff values of the PNI, fibrinogen, NLR, PLR, SII, and CRP/Alb were 49.5, 397ng/dl, 2.5, 154, 556, and 0.05, respectively. Multivariate analysis showed that age, PLR, TNM stage, and chemotherapy were the independent prognostic factors for advanced gastric cancer (AGC). Adjuvant chemotherapy improved the long-term prognosis of patients with PLR ≥154, but chemotherapy had no significant effect on the survival of patients with PLR <154.Conclusions: Our findings show that higher PLR (≥154) is an independent risk factor for poor prognosis in GC patients. Besides, PLR can predict adjuvant chemotherapy (oxaliplatin/5-fluorouracil combination) response in patients with GC after surgery.

scholarly journals Clinical significance of peripheral blood-derived inflammation markers in advanced gastric cancer after radical resection

2020 ◽  
Author(s):  
Lihu Gu ◽  
Mian Wang ◽  
Xuena Cui ◽  
Jiahang Mo ◽  
Lingling Yuan ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Multivariate Analysis ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Peripheral Blood ◽  
Inflammatory Markers ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Inflammation Markers ◽  
Optimal Cutoff

Abstract Background: The prognostic significance of peripheral blood-derived inflammation markers in patients with gastric cancer (GC) has not been elucidated. This study aimed to investigate the relationship between systemic inflammatory markers and GC prognosis.Methods: A prospective observational cohort study involving 598 patients was conducted to analyze the prognosis of GC based on systemic inflammatory markers. The following peripheral blood-derived inflammation markers were evaluated: the neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), systemic immune-inflammation index (SII), C-reactive protein/albumin (CRP/Alb) ratio, Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), prognostic nutrition index (PNI), and prognostic index (PI). The receiver operating characteristics (ROC) curve and the Youden index were used to determine the optimal cutoff values. Univariate and multivariate analysis of prognostic factors was conducted accordingly.Results: The optimal cutoff values of the PNI, fibrinogen, NLR, PLR, SII, and CRP/Alb were 49.5, 397ng/dl, 2.5, 154, 556, and 0.05, respectively. Multivariate analysis showed that age, PLR, TNM stage, and chemotherapy were the independent prognostic factors for advanced gastric cancer (AGC). Adjuvant chemotherapy improved the long-term prognosis of patients with PLR ≥154, but chemotherapy had no significant effect on the survival of patients with PLR <154.Conclusions: Our findings show that higher PLR (≥154) is an independent risk factor for poor prognosis in GC patients. Besides, PLR can predict adjuvant chemotherapy (oxaliplatin/5-fluorouracil combination) response in patients with GC after surgery.

Search for biomarkers of stage II/III gastric cancer and development of individualized therapy.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 4068-4068
Author(s):  
Takashi Oshima ◽  
Naoya Sakamoto ◽  
Takaki Yoshikawa ◽  
Yasushi Rino ◽  
Chikara Kunisaki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factors ◽  
Adjuvant Chemotherapy ◽  
Treatment Outcomes ◽  
Gastric Cancer Cell ◽  
Stage Ii ◽  
Individualized Therapy ◽  
Gastric Cancer Cell Lines ◽  
Resected Stage ◽  
New Biomarkers

4068 Background: Standard therapy for stage II/III gastric cancer is curative resection followed by adjuvant chemotherapy. Treatment outcomes are expected to be further improved by the development of individualized therapy based on new biomarkers. We have extracted mRNA from frozen specimens of gastric cancer to construct a cDNA bank and searched for new biomarkers of stage II/III gastric cancer. We report currently available results. Methods: The study group comprised 256 patients with stage II/III gastric cancer in whom at least 5 years had passed since surgery (among whom 149 received S-1 as adjuvant chemotherapy). A total of 130 genes were selected on the basis of the results of comprehensive DNA microarray analyses and extraction from serial analysis of gene expression (SAGE) libraries, and other studies. Relative expression levels of each gene in gastric cancer tissue and adjacent normal mucosa were measured by quantitative PCR, and the relations between clinicopathological factors and treatment outcomes were studied. In addition, using 9 types of gastric cancer cell lines, we knocked down the new cancer biomarkers obtained in this study with small interfering RNA (siRNA) and performed functional analysis. Results: In patients with resected stage II/III gastric cancer, INHBA, IGF-1R, CLDN7, and DPD genes were independent prognostic factors. In the subgroup of patients who received S-1-based adjuvant chemotherapy, IGF-1R, INHBA, SULF1, REG4, MMP11, and KIAA1199 genes were independent prognostic factors. Knockdown of the KIAA1199 gene with siRNA markedly inhibited the proliferative and invasive activities of the gastric cancer cell lines and lowered resistance to 5-fluorouracil. Conclusions: Investigatory studies of new biomarkers of gastric cancer identified prognostic factors for patients with resected stage II/III gastric cancer and those who received adjuvant chemotherapy with S-1. At present, the development of small molecule drugs that target KIAA1199 and the joint development of risk stratification tools with the goal of individualized therapy for stage II/III gastric cancer are ongoing.

Sign in / Sign up

Export Citation Format

Share Document